Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPAR signature
More importantly, eight out of ten mice found no H
Injectable GHK-Cu offers higher bioavailability than topical formulations
My protocol during this period: Retatrutide: 2mg weekly subcutaneous injection (ramped to 4mg by week 10) GHK-Cu: 1mg daily subcutaneous, rotated injection sites Cycle length: 12 weeks on, 4 weeks off Training: 4 days resistance training per week, 8,000 to 10,000 steps daily Protein intake: 130g daily minimum I sourced both from Red Fox Peptides
This is especially useful if you are working with a 90-day BUD and want to ensure the vial remains fully viable through the end
And then when COVID comes along, I'm like, Oh, that guy's a real problem